LPB Combined with QLB Using Single-needle Technique (LPQLB-SNT) for Hip Arthroplasty

NCT04266236 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-02-10

No results posted yet for this study

Summary

Total hip arthroplasty (THA) is one of the most successful orthopedic procedures to effectively relieve pain and restore function in patients with hip osteoarthritis, osteonecrosis of femoral head and hip fracture.The Lumbar Plexus Block (LPB) is currently used as the standard regional anesthesia technique to provide postoperative pain management after THA. The lumbar plexus (LP) originates from T12 to L5. In general, multiple-needle nerve blockade procedure is needed to block different branches of LP. Therefore, we need more time to finish the regional anethesia procedure and it's not easy for an inexperienced anesthesiologist to master the technique absolutely. In addition, multiple injections will increase the discomfort of the patients. We aim to investigate the effects of lumbar plexus combined with quadratus lumborum block using single-needle technique with Shamrock method as an alternative regional anesthesia.

Conditions

  • Hip Osteoarthritis
  • Anesthesia, Local
  • Hip Fractures
  • Osteonecrosis of Femoral Head

Interventions

PROCEDURE

L3 LPB

ultrasound-guided L3 lumbar plexus block

PROCEDURE

L4 LPB

ultrasound-guided L4 lumbar plexus block

PROCEDURE

T12 block

ultrasound-guided thoracic 12th segment nerve block

PROCEDURE

L3 QLB

ultrasound-guided quadratus lumborum block at L3 level

DRUG

0.375%ropivacaine 25 ml (Raropin)

0.375%ropivacaine (Raropin) 25ml will be given

DRUG

0.375%ropivacaine 40 ml (Raropin)

0.375%ropivacaine (Raropin) 40ml will be given

PROCEDURE

General anesthesia with tracheal intubation

General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation

Sponsors & Collaborators

  • Shanghai 6th People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-09
Primary Completion
2024-05-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04266236 on ClinicalTrials.gov